Search Results - "Danson, S.J"

66: Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum non-pemetrexed doublet chemotherapy by Marshall, R, Kakoudaki, M, Danson, S.J, Fisher, P.M, Hatton, M.Q, Lee, C.E, Das, T, Bates, E, Woll, P, Taylor, F

Get full text

67: Outcomes of patients in South Yorkshire who received maintenance pemetrexed treatment for non-squamous, non-small-cell cancer after induction chemotherapy with pemetrexed and cisplatin by Kakoudaki, M, Marshall, R, Danson, S.J, Fisher, P.M, Hatton, M.Q, Lee, C.E, Das, T, Bates, E, Woll, P, Taylor, F

Get full text

30 Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience by Khan, F, Ottensmeier, C, Popat, S, Danson, S.J

Get full text

41 Thirty-day lung cancer mortality: a retrospective review of patients in the North Trent Cancer Network by Bowen, K, Walkington, L, Evans, L.S, Danson, S.J

Get full text

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme by Khan, F, Ottensmeier, C, Popat, S, Dua, D, Dorey, N, Ellis, S, Szabo, M, Upadhyay, S, Califano, R, Chan, S, Lee, L, Ali, C.W, Nicolson, M, Bates, A.T, Button, M, Chaudhuri, A, Mulvenna, P, Shaw, H.M, Danson, S.J

“…Abstract Introduction Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to…”
Get full text

98 Oncolytic virus therapy for mesothelioma – a phase I trial of intrapleural seprehvir by Woll, P.J, Danson, S.J, Edwards, J.G, Fisher, P.M, Conner, J

Get full text

85: Systemic therapy in advanced NSCLC in the older patient: a network audit of non small cell lung cancer patients by Wilshaw, V, Das, T, Hatton, N, Fisher, P.M, Lee, C.E, Danson, S.J, Woll, P.J, Hatton, M.Q

Get full text

50: Outcomes of patients with malignant pleural mesothelioma treated with first line palliative cisplatin and pemetrexed chemotherapy, in South Yorkshire by Taylor, F, Viggars, A, Daniels, S, Danson, S.J, Fisher, P.M, Hatton, M.Q, Lee, C.E, Woll, P.J

Get full text

43 Use of first line maintenance chemotherapy with pemetrexed in patients with non squamous non small cell lung cancer – North Trent Cancer Network experience by Stansfield, R, Mohanamurali, J, Danson, S.J, Fisher, P.M, Hatton, M.Q, Lee, C.E, Woll, P.J

Get full text

25 Gefitinib in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-TK mutation – North Trent Cancer Network experience by Nugent, L, Das, T, Mohanamurali, J, Danson, S.J, Fisher, P.M, Hatton, M.Q, Lee, C.E, Woll, P.J

Get full text

46 Blood transfusion requirements of NSCLC patients receiving chemotherapy in the BTOG2 trial by Best, J, Young, R, Ddamba, J, Danson, S.J, Fisher, P.M, Foran, B, Hatton, M, Lee, C, Mohanamurali, J, Woll, P.J

Get full text

Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals by Bird, J, Nolan, M, Danson, S J

Get full text

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial by Corrie, P.G., Marshall, A., Nathan, P.D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C.G., Marples, M., Danson, S.J., Marshall, E., Board, R.E., Waterston, A.M., Nobes, J.P., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A., Westwell, S., Casasola, R., Chao, D., Patel, P.M., Ottensmeier, C.H., Farrugia, D., Eccles, B., Young, G., Barker, E.O., Harman, C., Weiss, M., Myers, K.A., Chhabra, A., Rodwell, S.H., Dunn, J.A., Middleton, M.R., Nathan, Paul, Lorigan, Paul, Dziewulski, Peter, Holikova, Sonja, Panwar, Udaiveer, Tahir, Saad, Faust, Guy, Thomas, Anne, Corrie, Pippa, Sirohi, Bhawna, Kelly, Charles, Middleton, Mark, Marples, Maria, Danson, Sarah, Lester, James, Marshall, Ernest, Ajaz, Mazhar, Houston, Stephen, Board, Ruth, Eaton, David, Waterston, Ashita, Nobes, Jenny, Loo, Suat, Gray, Gill, Stubbings, Helen, Gore, Martin, Harries, Mark, Kumar, Satish, Goodman, Andrew, Dalgleish, Angus, Martin-Clavijo, Agustin, Marsden, Jerry, Westwell, Sarah, Casasola, Richard, Chao, David, Maraveyas, Anthony, Patel, Poulam, Ottensmeier, Christian, Farrugia, David, Humphreys, Alison, Eccles, Bryony, Herbert, Chris, Price, Christopher, Brunt, Murray, Scott-Brown, Martin, Hamilton, Joanna, Hayward, Richard Larry, Smyth, John, Woodings, Pamela, Nayak, Neena, Burrows, Lorna, Wolstenholme, Virginia, Wagstaff, John, Nicolson, Marianne, Wilson, Andrew, Barlow, Clare, Scrase, Christopher, Podd, Timothy, Gonzalez, Michael, Highley, Martin, Grumett, Simon, Talbot, Toby, Nathan, Kannon, Coltart, Robert, Gee, Bruce

“…Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We…”
Get full text

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial by Corrie, P.G., Marshall, A., Nathan, P.D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C.G., Marples, M., Danson, S.J., Marshall, E., Houston, S.J., Board, R.E., Waterston, A.M., Nobes, J.P., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A., Westwell, S., Casasola, R., Chao, D., Maraveyas, A., Patel, P.M., Ottensmeier, C.H., Farrugia, D., Humphreys, A., Eccles, B., Young, G., Barker, E.O., Harman, C., Weiss, M., Myers, K.A., Chhabra, A., Rodwell, S.H., Dunn, J.A., Middleton, M.R.

Get full text

A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial by Peters, S., Danson, S.J., Hasan, B., Reinmuth, N., Majem, M., Tournoy, K.G., Mark, M.T., Pless, M., Cobo, M., Rodriguez-Abreu, D., Falchero, L., Massutí, B., Coate, L., von Moos, R., Zielinski, C.C., De Maio, E., O’Brien, M., Roschitzki-Voser, H., Dafni, U., Stahel, R.A.

Get full text

SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer by Crabb, S J, Danson, S J, Dunkley, D, Kalevras, M, Whitehead, A, Hill, S, Fines, K, Robb, C, Bennett, J, Ksiazek, L, Brown, S L, Evans, L, Serra, M, Jones, K, McDowell, C, Catto, J W, Huddart, R, Griffths, G

Get full text

Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1 by Danson, S.J., Johnson, P., Ward, T.H., Dawson, M., Denneny, O., Dickinson, G., Aarons, L., Watson, A., Jowle, D., Cummings, J., Robson, L., Halbert, G., Dive, C., Ranson, M.

“…This trial describes a first-in-man evaluation of RH1, a novel bioreductive drug activated by DT-diaphorase (DTD), an enzyme overexpressed in many tumours. A…”
Get full text